I'm LongbridgeAI, I can summarize articles.Lexaria Bioscience Corp. reported Q2026 results with $0 revenue and a diluted loss per share of ($0.08), narrowing net loss to ($1.99M) from ($3.79M) prior year. Revenue declined due to a strategic shift from B2B clients to licensing and pharmaceutical partnerships. The company completed Phase 1b GLP-1-H24-4 clinical studies, advanced R&D across multiple programs, secured FDA clearance for an IND-based hypertension program, and raised approximately $6.5M to fund operations into fiscal 2027.
Lexaria Bioscience Corp. reported results for the 2026 quarter with revenue of $0 and a diluted loss per share of ($0.08); net loss narrowed to ($1.99M) from ($3.79M) a year earlier.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $0 | $174K | (100%) |
| Net income² | ($1.99M) | ($3.79M) | 47.4% |
| Diluted EPS³ | ($0.08) | ($0.21) | 61.9% |
¹ Reported as “Revenue”. ² Reported as “Net loss attributable to Lexaria shareholders”. ³ Reported as “diluted loss per share”.
Business Highlights
- Completed the Phase 1b GLP-1‑H24‑4 clinical study and reported favorable safety and tolerability versus Rybelsus®.
- Advancing R&D across GLP-1, GIP, glucagon and CBD programs with multiple human and animal studies underway.
- Extended a materials transfer agreement with PharmaCO and received FDA clearance to proceed on an IND-based hypertension program.
- Revenue declined as the company shifted from prior B2B clients toward licensing and pharmaceutical development partnerships.
- Raised approximately $6.5M in two registered offerings to fund clinical trials and R&D into fiscal 2027.
Original SEC Filing: Lexaria Bioscience Corp. [ LEXX ] - 10-Q - Jul. 13, 2026